Argentex Announces Additional Drill Results from its Pinguino Silver-Gold Project Including 3 Metres Averaging 712.7 g/t Ag and 8.24 g/t Au
Argentex Mining Corporation (TSX VENTURE:ATX)(AGXMF) ("Argentex" or the "Company") is pleased to announce drilling results from an additional 36 holes of its 58-hole, 3,003-metre 2013 Phase IX resource development drill program at its 100%-owned Pingüino silver and gold project, located in Santa Cruz Province, Argentina. To date, the Company has received results from 44 reverse circulation ("RC") holes, with results from the final 14 RC holes still pending.
CDTi Receives EPA Verifications for Purifilter(R)EGR and Purifilter(R)OR
Clean Diesel Technologies, Inc. (CDTI) ("CDTi"), a leader in advanced emissions control solutions, is pleased to announce that it has received two significant emission reduction product verifications from the U.S. Environmental Protection Agency (the "EPA") for use in heavy duty highway truck engines and off-road engines.
The uniquely designed Purifilter(R)EGR, featuring CDTi's proprietary MPC(R) technology, is a passively-regenerating diesel particulate filter that provides exceptional filtration and regeneration efficiency for the removal of particulate matter. The EPA first verified Purifilter(R)EGR for 2002-2010 heavy duty highway truck engines in November 2012. In October 2013, the EPA extended the verification to cover all exhaust gas recirculation ("EGR") and non-EGR heavy duty highway engines certified with particulate matter emissions at or below 0.1 g/hp-hr manufactured between 1993 and 2010.
Oxygen Biotherapeutics Provides a Business Review and Update in Conjunction with Filing of Second Quarter Fiscal Year 2014 Financials
Oxygen Biotherapeutics, Inc.,(“OBI”) (OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that it has filed its Quarterly Report on Form 10-Q for its second quarter fiscal year (FY) 2014 ended October 31, 2013. In connection with that filing, the company is providing a review of recent achievements and an update on business operations and future milestones.
Alimera Sciences and FDA Enter Into Labeling Discussions for ILUVIEN®, Agree Advisory Committee No Longer Necessary
Alimera Plans to Respond to October Complete Response Letter in First Quarter 2014
Alimera Sciences, Inc. (ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has entered into labeling discussions with the U.S. Food and Drug Administration (FDA) for ILUVIEN® and, as a result, reached an agreement with the FDA that Alimera's participation in the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting was no longer necessary. Alimera will focus instead on drafting its response to the Complete Response Letter (CRL) received from the FDA in October 2013 with a goal of submitting the response in the first quarter of 2014.
Harland Clarke Holdings Corp. to Acquire Valassis for $34.04 per Share in Cash
Combination Will Create Leading Diversified Global Transaction and Marketing Services and Media Delivery Company
Harland Clarke Holdings Corp., a leading provider of best-in-class integrated payment solutions and marketing services, and Valassis (VCI), a leader in intelligent media delivery, today announced that they have entered into a definitive merger agreement under which Harland Clarke Holdings will acquire Valassis.
Under the terms of the agreement, Harland Clarke Holdings, a wholly owned subsidiary of MacAndrews & Forbes Holdings Inc., will acquire all of the outstanding shares of Valassis for $34.04 per share in cash, representing a transaction value of approximately $1.84 billion.
FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies
-- Phase 2 Program Expected to Begin Next Quarter --
Omeros Corporation (OMER) today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for prevention of complement-mediated thrombotic microangiopathies (TMAs).
Depomed Acquires CAMBIA® (Diclofenac Potassium for Oral Solution) Migraine Medicine from Nautilus Neurosciences for $48.7 Million
Depomed, Inc. (DEPO) today announced that it has acquired the United States rights to CAMBIA® (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million. In addition, Depomed may pay Nautilus up to an additional $5 million based on the achievement of certain annual net sales milestones. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults 18 years of age or older.
Renewable Energy Group, Inc. Agrees to Acquire Syntroleum Corporation
Acquisition Would Add Renewable Diesel, Other Advanced Technologies to REG’s Product Line
Renewable Energy Group, Inc.® (REGI) and Syntroleum Corporation (SYNM) announced today that they have entered into an asset purchase agreement pursuant to which REG would acquire substantially all of the assets of Syntroleum Corporation, and assume substantially all of the material liabilities of Syntroleum. The terms of the transaction call for Syntroleum to receive 3,796,000 shares of REG common stock (subject to reduction in the event that the aggregate market value of the REG common stock to be issued would exceed $49 million or if the cash transferred to REG is less than $3.2 million).
Inventergy Inc. Enters Into Merger Agreement With eOn Communications
Inventergy Inc. and eOn Communications Corporation (NASDAQ: EONC) have announced today that they have entered into a merger agreement whereby Inventergy will merge into a wholly-owned subsidiary of eOn. Upon satisfaction of all of the conditions to completing the merger, eOn Communications will be renamed Inventergy Global, Inc. Upon completion of the merger, Inventergy stockholders will receive shares of eOn stock, such that the Inventergy stockholders in the aggregate will control eOn after the merger.
Asanko Gold to Acquire PMI to Create an Emerging Mid-Tier Gold Producer
Asanko Gold Inc. ("Asanko" or the "Company") (AKG.TO)(NYSE MKT:AKG)(NYSE Amex:AKG) and PMI Gold Corporation ("PMI") (PMV.TO)(PVM.AX) are pleased to announce that they have entered into a definitive agreement whereby Asanko will acquire all of the common shares of PMI (the "Business Combination") to create an emerging mid-tier gold producer with a clear pathway to 400,000 ounces of annual gold production. A joint conference call and webcast hosted by Peter Breese and Peter Bradford will be held today at 4:00pm (EST) and 1:00pm (PST) (8:00am Wednesday in Sydney) to discuss this transaction. Call-in details are provided at the end of this release.
LGX Oil + Gas Inc. Announces Significant Big Valley Well Test Results
LGX Oil + Gas Inc. ("LGX" or the "Company") (TSXV:OIL.V) is pleased to provide completion results from recent southern Alberta drilling activity. LGX's Big Valley (Three Forks) Formation horizontal well at 13-2-9-24 W4M was recently completed with a 20 stage hydraulic fracture stimulation and has achieved the following extended production test results.
The 13-2 well has been flowing back for 136 hours up a 4.5 inch diameter frac string and has produced 9,360 Bbl of 31 degree API light oil for an average daily rate of approximately 1,650 Bbl oil per day and 570 Mcf per day of associated solution gas for an oil equivalent rate of 1,745 BOE per day over the test period.
Navidea Biopharmaceuticals Submits Supplemental New Drug Application (sNDA) for Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer
- sNDA includes data from successful Phase 3 study in patients with head and neck cancer -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node (SLN) detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month. Lymphoseek is currently approved for use in lymphatic mapping procedures that are performed to aid in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.
Gold Resource Corporation Expands Switchback Discovery Intercepting Multiple High-Grade Mineralized Veins Over 68 Meter Interval
Gold Resource Corporation (NYSE MKT: GORO) (the "Company") announces the expansion of its high-grade Switchback discovery intercepting multiple veins over a 68 meter wide interval. Step-out drilling includes 5.27 meters of 2.93 grams per tonne (0.09 oz/ton) gold, 0.89 meters of 16.95 grams per tonne (0.49 oz/ton) gold and 1.60 meters of 575 grams per tonne (16.79 oz/ton) silver. Gold Resource Corporation is a gold and silver producer with operations in the southern state of Oaxaca, Mexico. The Company has returned over $91 million to shareholders in monthly dividends since declaring production July 1, 2010, and offers shareholders the option to convert their cash dividends into physical gold and silver and take delivery.
Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement
Neptune Technologies & Bioressources Inc. ("Neptune") (NEPT) (NTB.TO), Acasti Pharma Inc. ("Acasti") (ACST) (APO.V), a Neptune subsidiary, and Aker BioMarine AS, Aker BioMarine Antarctic AS and Aker BioMarine Antarctic USA (collectively "AKBM") jointly announce a settlement and license agreement that will result in the dismissal of all AKBM respondents from the on-going ITC investigation brought by Neptune and Acasti, as well as the dismissal of all current lawsuits brought by Neptune against AKBM and companies in its value chain.
Frontier Communications to Acquire AT&T’s Wireline Residential and Business Services and Associated Assets in Connecticut
All-cash Transaction is Accretive to Free Cash Flow Per Share in the First Year No Change to Frontier’s Annual Dividend; Improves Payout Ratio $200 Million in Annual Cost Synergies and Savings
Frontier Communications Corporation (FTR) announced today that it has entered into a definitive agreement with AT&T, Inc. (NYSE:T) to acquire AT&T’s wireline business and statewide fiber network that provides services to residential, commercial and wholesale customers in Connecticut. As part of the transaction, Frontier will also acquire AT&T’s U-verse video and satellite TV customers in Connecticut. Frontier will pay AT&T $2 billion in cash for the business and related assets. Frontier’s extensive experience operating local and national communications networks and providing communications services to residential and commercial customers throughout the country will contribute to the success of this transaction.
Primero to acquire Brigus Gold and create a diversified, Americas based mid-tier gold producer
Primero Mining Corp. ("Primero" or the "Company") (TSX:P, NYSE:PPP, ASX:PPM) and Brigus Gold Corp. ("Brigus") (NYSE:BRD; TSX:BRD) today announced that they have entered into an arrangement agreement (the "Arrangement Agreement") whereby Primero will acquire all outstanding common shares of Brigus pursuant to a plan of arrangement (the "Arrangement") to create a diversified, Americas based mid-tier gold producer.
Pursuant to the Arrangement, Primero will acquire each outstanding Brigus common share for 0.175 of a Primero common share (the "Exchange Ratio"). In addition, Brigus shareholders will receive 0.1 of a common share in a newly incorporated company ("SpinCo") for each Brigus common share as part of the Arrangement.
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) -
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML). The early results show that BL-8040, as a stand-alone therapy and in combination with high-dose Cytarabine (Ara-C), is safe at all doses tested to date, and triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood, thereby increasing the vulnerability of the cells to chemotherapy treatment.
AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO™
- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso -
AcelRx Pharmaceuticals, Inc. (ACRX) and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO™ (previously known as ARX-01) for potential use in pain treatment within or dispensed by a hospital, hospice, nursing home or other medically supervised setting. ZALVISO, a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device is AcelRx's lead program. AcelRx retains all rights in remaining countries, including the U.S. and Asia.
Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology
Results Show Improved Survival Against Aggressive Brain Cancer; More Than 90% of Patients Alive After Six Months
Agenus Inc. (AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme (GBM) patients of three to nine months1-7. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.
Avago Technologies to Acquire LSI Corporation for $6.6 Billion in Cash
Silver Lake Partners to Support Transaction With $1 Billion Investment in AvagoPositions Avago as a leader in enterprise storage Expands market position and brings valuable system-level expertise in wired infrastructure Diversifies revenue and scales up Avago across multiple attractive end markets Significantly and immediately accretive to Avago free cash flow and EPS on a non-GAAP basis $200 million of annual operating synergies expected by the end of fiscal year 2015